Back to Agenda
Session 3B: Understanding the Effects of 2’-MOE ASO Treatment on PLT Count in Non-Human Primates and Humans
Session Chair(s)
Scott Henry, PhD
Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States
This session will examine the overall experience with this class of oligonucleotides on PLT count in both monkeys and humans using a database comprised of multiple compounds. Comparisons will be made between monkeys and humans, include special patient populations that have recently reported servere thrombocytopenia. Background information on PLT biology and the current status investigation into the mechanism of potential PLT changes will be presented.
Learning Objective :
Speaker(s)
Session Co-Chair
Ronald Wange, PhD
FDA, United States
Associate Director for Pharm/Tox, OND, CDER
PLT Biology 101: Platelets and the Immune Continuum
Joseph E. Italiano, PhD
Brigham and Women’s Hospital, United States
Director Cellular and Molecular Pathology, Division of Hematology
Characterizing the Nature and the Mechanism of PLT Changes Observed in Monkeys Treated with 2’ MOE ASO
Scott Henry, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Nonclinical Development
Human PLT Database for 2’-MOE ASO and Recent Expereince in FCS and TTR Phase 3 Trials
Richard Stephen Geary, PhD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Drug Development
Panel Discussion
Panel Discussion
All Session Speakers, United States
Have an account?